Regulators advanced two targeted oncology approvals. The U.S. FDA approved ziftomenib (Komzifti), a selective oral menin inhibitor from Kura Oncology/Kyowa Kirin, for relapsed/refractory NPM1‑mutant acute myeloid leukemia ahead of its PDUFA date. Separately, the FDA granted accelerated approval to Bayer’s Hyrnuo for advanced non‑small cell lung cancer harboring HER2 mutations, positioning it in direct competition with a recent Boehringer Ingelheim oral HER2 inhibitor. Both approvals expand precision‑medicine options for genomically defined patient subsets.